Ultragenyx Pharmaceutical Inc (RARE) Price Prediction & ForecastRAREUltragenyx Pharmaceutical Inc

Alphio's RARE stock price prediction model matches the current Ultragenyx Pharmaceutical Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $14.95 (-1.42%). The 1-week path is $15.10 (-0.49%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Ultragenyx Pharmaceutical Inc (RARE) is a good buy right now due to its recent FDA approval of Fayuvi, which is expected to drive revenue growth, and the sale of a Priority Review Voucher for $210 million, providing non-dilutive capital. The current price of $15.48 is significantly below the raised analyst price target of $39, suggesting a potential upside of 166%. Additionally, the RSI of 61.305 indicates that the stock is in a healthy momentum range, which supports a buying opportunity. However, the company still faces risks, including a substantial year-to-date decline of 34.41% and a negative net income of $92 million in the latest quarter, which investors should consider before making a decision.

Ultragenyx Pharmaceutical Inc (RARE) last closed at $15.17, gaining +1.81%. These facts feed the 1-day and 1-week RARE price prediction above.